Akiyama T, Tominaga M, Davoodi A, Nagamine M, Blansit K, Horwitz A, Carstens MI, Carstens E. Roles for substance P and gastrin-releasing peptide as neurotransmitters released by primary afferent pruriceptors. J Neurophysiol 109: 742-748, 2013. First published November 14, 2012 doi:10.1152/jn.00539.2012.-Recent studies support roles for neurokinin-1 (NK-1) and gastrin-releasing peptide (GRP) receptor-expressing spinal neurons in itch. We presently investigated expression of substance P (SP) and GRP in pruritogen-responsive primary sensory neurons and roles for these neuropeptides in itch signaling. Responses of dorsal root ganglion (DRG) cells to various pruritogens were observed by calcium imaging. DRG cells were then processed for SP, GRP, and isolectin B-4 (IB4; a marker for nonpeptidergic neurons) immunofluorescence. Of pruritogen-responsive DRG cells, 11.8 -26.8%, 21.8 -40.0%, and 21.4 -26.8% were immunopositive for SP, GRP, and IB4, respectively. In behavioral studies, both systemic and intrathecal administration of a NK-1 receptor antagonist significantly attenuated scratching evoked by chloroquine and a protease-activated receptor 2 agonist, SLIGRL, but not histamine, bovine adrenal medulla peptide 8-22 (BAM8-22), or serotonin. Systemic or intrathecal administration of a GRP receptor antagonist attenuated scratching evoked by chloroquine and SLIGRL but not BAM8-22 or histamine. The GRP receptor antagonist enhanced scratching evoked by serotonin. These results indicate that SP and GRP expressed in primary sensory neurons are partially involved as neurotransmitters in histamine-independent itch signaling from the skin to the spinal cord. dorsal root ganglion cell; itch; mouse; scratching ALTHOUGH CHRONIC ITCH IS A burdensome clinical problem that decreases the quality of life (Weisshaar et al. 2006) , the neuronal mechanisms of itch are still not fully understood. Recent studies have implicated histamine-dependent and histamine-independent pathways in transmitting itch. One histamine-independent itch pathway involves a family of over 50 Mas-related G protein-coupled receptors (Mrgprs), including MrgprAs, MrgprB4-5, MrgprC11, and MrgprD, which are restricted to small-diameter dorsal root ganglion (DRG) neurons in mice (Dong et al.
in a dose-dependent manner (Akiyama et al. 2009; Shimada et al. 2006; Ui et al. 2006) .
Recent studies support roles for neurokinin-1 (NK-1) and gastrin-releasing peptide (GRP) receptor-expressing spinal neurons in itch Sun et al. 2009 ). Both NK-1 and GRP receptors are expressed in neurons in the spinal superficial dorsal horn Sun et al. 2009 ). Intrathecal injection of saporin-conjugated bombesin eliminated GRP receptor-expressing spinal neurons in mice and reduced scratching elicited by a variety of pruritogens. In addition, intrathecal injection of saporin-conjugated substance P (SP) eliminated the NK-1 receptor-expressing spinal neurons in rats and reduced scratching elicited by serotonin (5-HT). Nevertheless, the roles for SP and GRP in the spinal transmission of itch signals are not fully understood. A GRP receptor antagonist partially reduced scratching elicited by a PAR-2 agonist, compound 48/80, and chloroquine (Sun and Chen 2007) , whereas GRP receptor knockout mice did not exhibit a reduction in scratching evoked by histamine, 5-HT, or endothelin-1 (Sun et al. 2009 ). It is reported that GRP is not essential to activate the GRP receptor, which heterodimerizes with the -opioid receptor isoform MOR1D in mouse superficial dorsal horn neurons and may mediate opioid-induced itch . A NK-1 receptor antagonist suppressed scratching elicited by trypsin (Costa et al. 2008) , whereas deletion of the preprotachykinin A gene that encodes SP and NK-A in mice did not reduce 5-HT-evoked scratching (Cuellar et al. 2003) . In this study, we determined the expression of SP and GRP in pruritogen-sensitive primary sensory neurons. We further investigated whether antagonists of the NK-1 or GRP receptor attenuated scratching evoked by different types of pruritogens in mice.
MATERIALS AND METHODS
Calcium imaging. A total of 43 adult male C57/BL6 mice (7-9 wk old; 18 -21 g; Simonsen Laboratories, Gilroy, CA) was used under a protocol approved by the University of California (UC), Davis, Institutional Animal Care and Use Committee. The animal was euthanized under sodium pentobarbital anesthesia, and upper-to midcervical DRGs were acutely dissected and enzymatically digested at 37°C for 10 min in HBSS (Invitrogen, Carlsbad, CA) containing 20 U/ml papain (Worthington Biochemical, Lakewood, NJ) and 6.7 mg/ml L-cysteine (Sigma, St. Louis, MO), followed by 10 min at 37°C in HBSS containing 3 mg/ml collagenase (Worthington Biochemical). The ganglia were then mechanically triturated using firepolished glass pipettes. DRG cells were pelleted; suspended in MEM with Earle's balanced salt solution (Gibco, Life Technologies, Carlsbad, CA) containing 100 U/ml penicillin, 100 g/ml streptomycin (Gibco, Life Technologies), 1ϫ vitamin (Gibco, Life Technologies), and 10% horse serum (Quad Five, Ryegate, MT); plated on poly-Dlysine-coated glass coverslips; and cultured for 16 -24 h. DRG cells were incubated in Ringer's solution (pH 7.4, 140 mM NaCl, 4 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 10 mM HEPES, and 4.54 mM NaOH) with 10 M Fura-2 AM and 0.05% of Pluronic F-127 (Invitrogen). Coverslips were mounted on a custom-made aluminum perfusion block and viewed through an inverted microscope (Nikon TS100, Technical Instruments, Burlingame, CA). Fluorescence was excited by UV light at 340 nm and 380 nm alternately, and emitted light was collected via a CoolSNAP camera attached to a Lambda LS lamp and a Lambda optical filter changer (Sutter Instrument, Novato, CA). Ratiometric measurements were made using Simple PCI software (Hamamatsu, Sewickley, PA) every 3 s.
Solutions were delivered by a solenoid-controlled eight-channel perfusion system (ValveLink, AutoMate Scientific, San Francisco, CA). Two of the following agents were delivered in randomized order: chloroquine (300 M), BAM8-22 (10 M), histamine (100 M), and the PAR-2 agonist SLIGRL-NH2 (100 M). Potassium, at a concentration of 144 mM, was always delivered at the end of each experiment. Stimulus duration was 30 s (10 s for capsaicin). Ratios were normalized to baseline. Cells were judged to be sensitive if the ratio value increased by Ͼ10% of the resting level following chemical application. Only cells responsive to high potassium were included for analysis. After the experiment, coverslips were marked with a diamond pen to provide landmarks for alignment with subsequent immunohistofluoresence labeling of the same cells.
Immunocytochemistry. After calcium imaging, DRG cells in the culture dish were fixed in formalin, followed by 30% sucrose, and then incubated with 5% normal serum. They were immunostained with anti-GRP antibody (1:500; ImmunoStar, Hudson, WI), anti-SP antibody (1:500; Millpore, Billerica, MA), or biotinylated isolectin B-4 (IB4; 1:200; Vector Laboratories, Burlingame, CA) at 4°C overnight, followed by incubation with the corresponding secondary antibody conjugated with Alexa Fluor 488 (1:500; Life Technologies, Grand Island, NY) or avidin-Texas Red (1:100; Life Technologies) for 2 h. Images were captured using a fluorescence microscope (Nikon Eclipse Ti; Technical Instruments). Immunohistofluorescent images were aligned with images captured during calcium imaging to determine the percentages of pruritogen-responsive DRG cells that were double labeled for SP, GRP, or IB4.
Behavioral scratching studies. Experiments were conducted using adult male C57/BL6 mice (19 -26 g; Simonsen Laboratories), again under a protocol approved by the UC Davis Animal Care and Use Committee. The fur on the rostral back was shaved, and mice were habituated to the Plexiglas recording arena 1 wk prior to testing. In a first set of experiments, vehicle [saline, subcutaneously (sc)], the GRP receptor antagonist RC-3095 (0.3 mg/kg sc; Sigma), or the NK-1 antagonist L-733060 (10 mg/kg ip; Tocris Bioscience, Minneapolis, MN) was administered systemically, followed 30 min later by intradermal (id) injection (10 l) of one of the following: vehicle (isotonic saline), histamine (271 nmol; Sigma), PAR-2 agonist SLIGRL-NH2 (76 nmol; Quality Controlled Biochemicals, Hopkinton, MA), serotonin (5-HT; 47 nmol; Alfa Aesar, Ward Hill, MA), chloroquine (193 nmol; Sigma), or BAM8-22 (50 nmol; Genemed Synthesis, San Antonio, TX). In a second set of experiments, vehicle (saline; 5 l), RC-3095 (0.3 nmol/5 l), or L-733060 (22.7 nmol/5 l) was administered intrathecally via lumbar puncture, 5 min prior to id injection of one of the pruritogens noted above. In a third set of experiments, mice received an id microinjection of either 10 l serotonin (47 nmol) or a combination of serotonin (47 nmol) and RC-3095 (0.6 nmol). Microinjections were made id in the nape of the neck using a 30G needle attached to a Hamilton microsyringe by PE-50 tubing. Immediately after the injection, the mouse was placed into the arena and videotaped from above for 30 min. Generally, three to four mice were injected and videotaped simultaneously. Immediately after commencing videotaping, all investigators left the room.
Videotapes were reviewed by investigators blinded to the treatment, and the number of scratch bouts was counted at 5-min intervals. A scratch bout was defined as one or more rapid back-and-forth hind-paw motions directed toward and contacting the injection site, ending with licking or biting of the toes and/or placement of the hind paw on the floor. Hind-paw movements directed away from the injection site (e.g., ear-scratching) and grooming movements were not counted. For analysis of the time course of scratching, two-way repeated-measures ANOVA followed by Student-Newman-Keuls test was used to compare the mean number of scratch bouts/5-min interval after pruritogen injection without vs. with pretreatment. One-way ANOVA followed by the Bonferroni post-test was used to compare the total number of scratch bouts across pretreatment groups. In all cases, P Ͻ 0.05 was considered to be significant.
RESULTS

Calcium imaging of DRG cells.
A total of 8,248 DRG cells was imaged for responsiveness to chloroquine, BAM8-22, histamine, and the PAR-2 agonist SLIGRL. The percentages of responsive DRG cells were as follows: chloroquine 9.8%, BAM8-22 3.4%, histamine 19.1%, and the PAR-2 agonist 2.5%. These values are consistent with previous studies (Akiyama et al. 2010; Liu et al. 2009; Wilson et al. 2011) . Additional details regarding this DRG cell population have been published separately (Akiyama et al. 2012) .
Immunofluorescent labeling of pruritogen-responsive DRG cells. Following calcium imaging, the DRG cells were fixed and immunostained with an antibody directed against SP, GRP, or IB4. A total of 2,696 DRG cells was labeled. Fig. 1A shows a fluorescence image of a DRG cell that responded to chloroquine in calcium imaging, and Fig. 1B shows that the same cell was immunopositive for SP. Fig. 1 , C-E, shows examples of DRG cells immunopositive for SP, GRP, and IB4, respectively.
Overall, 33.2% of all DRG cells examined were immunopositive for SP, 27.2% for GRP, and 23.5% for IB4, consistent with previous studies (Caterina et al. 2000; Chen et al. 2006; Dirajlal et al. 2003; Sun and Chen 2007; Tominaga et al. 2009 ). Of the DRG cells that responded to chloroquine, 26.8%, 25.3%, and 21.4% were immunpositive for SP, GRP, and IB4, respectively (Fig. 1F) . Of the BAM8-22-responsive cells, 15.9%, 40.0%, and 17.6% were immunpositive for SP, GRP, and IB4, respectively (Fig. 1G) . Of the histamine-responsive cells, 18.1%, 21.8%, and 45.5% were immunpositive for SP, GRP, and IB4, respectively (Fig. 1H) . Of the SLIGRL-NH2-responsive cells, 11.8%, 30.0%, and 17.2% were immunpositive for SP, GRP, and IB4, respectively (Fig. 1I) .
Systemic injection of NK-1 and GRP receptor antagonists reduces scratching elicited by certain pruritogens. The time course of scratching elicited by id injection of each pruritogen is shown in Fig. 2 , A-E, for chloroquine, BAM8-22, histamine, SLIGRL-NH2, and 5-HT, respectively. In all cases, maximal scratching occurred within the initial 5-to 10-min postinjection and decreased within 20 -30 min.
The NK-1 antagonist L-733060, but not the GRP receptor antagonist RC-3095, significantly attenuated chloroquine-evoked scratching ( Figs. 2A and 3A ; P Ͻ 0.05). Neither the NK-1 nor the GRP receptor antagonist had any significant effect on scratching elicited by or histamine (Figs. 2C  and 3C ). Both the NK-1 and GRP receptor antagonist (RC-3095) significantly attenuated SLIGRL-NH2-evoked scratching (Figs.  2D and 3D) . The GRP receptor antagonist significantly enhanced 5-HT-evoked scratching ( Figs. 2E and 3E ; P Ͻ 0.05).
Intrathecal injection of NK-1 and GRP receptor antagonists reduce scratching elicited by certain pruritogens. Consistent with the results following its systemic administration, intrathecal injection of the NK-1 antagonist L-733060 attenuated chloroquineevoked scratching ( Fig. 4A ; P Ͻ 0.05), and intrathecal injection of the GRP receptor antagonist significantly attenuated chloroquineevoked scratching ( Fig. 4A ; P Ͻ 0.05), in contrast to the lack of antagonist effect when administered systemically. Neither the NK-1 nor the GRP receptor antagonist had any significant effect on scratching elicited by BAM8-22 (Fig. 4B) or histamine (Fig.  4C) . Both the NK-1 and GRP receptor antagonist significantly attenuated SLIGRL-NH2-evoked scratching (Fig. 4D) .
Injection (id) of the GRP receptor antagonist significantly enhanced 5-HT-evoked scratching. Injection (id) of the GRP receptor antagonist elicited a modest but statistically significant increase in scratching [15.8 Ϯ 2.8 (SE) scratch bouts/15 min] compared with id saline (5.8 Ϯ 3.3). Injection (id) of the GRP receptor antagonist also significantly enhanced 5-HT-evoked scratching ( Fig. 4E ; P Ͻ 0.05), similar to its effect when administered systemically.
DISCUSSION
A substantial proportion of pruritogen-responsive DRG cells expressed SP or GRP. Antagonists of the NK-1 and/or GRP receptor reduced scratching elicited by the SLIGRL-NH2 and chloroquine, implying roles for the neuropeptide transmitters SP and GRP in the spinal transmission of a nonhistaminergic itch.
Neuroanatomical and molecular characterization allows C fibers to be categorized as either peptidergic neurons that release neuropeptides, including SP and GRP, or nonpeptidergic neurons that bind IB4 (Basbaum et al. 2009; Sun and Chen 2007) . It was reported originally that Mrgprs, including those that bind chloroquine or BAM8-22, were expressed predominantly in nonpeptidergic neurons (Dong et al. 2001; Zylka et al. 2003) . However, Mrgprs have been reported more recently to also be expressed in peptidergic neurons (Liu et al. , 2010 . Injection (id) of chloroquine induced expression of Fos, a marker for neuronal activation, in neurons located in the superficial spinal dorsal horn dorsal to and within the region of IB4 labeling, implying that chloroquine activates both peptidergic and nonpeptidergic neurons (Han et al. 2012) . Consistent with these findings, we showed that subpopulations of DRG cells responsive to chloroquine or BAM8-22 were also immunoreactive for SP and GRP and were labeled with IB4.
Approximately one-half of histamine-responsive DRG cells was immunoreactive for IB4. An earlier study similarly re- ported that approximately three-fourths of histamine-responsive DRG cells were IB4 positive (Han et al. 2006) . In this latter study, a deficiency of PLC␤3 in IB4-positive DRG cells abolished their responses to histamine. We presently observed that the incidence of IB4 expression in histamine-sensitive DRG cells was much greater compared with that of SP or GRP (Fig. 1H) . This is consistent with a previous report that id injection of histamine elicited Fos expression in superficial dorsal horn neurons located primarily within the region of IB4 labeling, suggesting that histamine activates mainly nonpeptidergic neurons (Nakano et al. 2008 ). SLIGRL-NH2-responsive DRG cells were immunoreactive for SP or GRP, consistent with previous reports (Nakano et al. 2008; Steinhoff et al. 2000) . In the present study, a substantial proportion of SLIGRL-NH2-responsive DRG cells was immunoreactive for IB4, suggesting that the SLIGRL-NH2 also activated nonpeptidergic neurons.
The NK-1 antagonist partially inhibited scratching evoked by chloroquine and SLIGRL-NH2, and SP was expressed in subpopulations of chloroquine-and SLIGRL-NH2-responsive DRG cells. These findings are consistent with the report that a NK-1 antagonist suppressed scratching elicited by tryptase (Costa et al. 2008) . NK-1 receptors are expressed in 30% of DRG neurons and may be responsible for itch signaling through a possible autocrine and paracrine action of SP (Zhang et al. 2007 ). However, the NK-1 antagonist failed to inhibit scratching elicited by histamine, 5-HT, or BAM8-22. In accordance with the present results, deletion of the preprotachykinin A gene in mice did not affect 5-HT-evoked scratching (Cuellar et al. 2003) . 5-HT-evoked scratching was suppressed following neurotoxic destruction of NK-1 receptor-expressing neurons in the superficial dorsal horn , implying that neurons expressing NK-1 receptors, rather than SP per se, are involved in certain types of itch signaling.
The GRP receptor antagonist partially suppressed SLIGRL-NH2-evoked scratching, and GRP was expressed in a subpopulation of SLIGRL-NH2-responsive DRG cells. These findings are largely consistent with recent reports that the GRP receptor is involved in itch (Sun and Chen 2007; Sun et al. 2009 ). Whereas systemic injection of the GRP antagonist only weakly inhibited chloroquine-evoked scratching, intrathecal injection of the GRP receptor antagonist significantly suppressed chloroquine-evoked scratching, consistent with earlier findings (Sun and Chen 2007; Sun et al. 2009 ). This difference might depend on the route of administration of the antagonist (intrathecal vs. systemic). Systemic injection of the GRP receptor antagonist RC-3095 presumably elicited weak scratching via an action at peripheral GRP receptors. The GRP receptor antagonist did not inhibit histamine-elicited scratching, which is also consistent with earlier findings (Sun and Chen 2007; Sun et al. 2009 ).
It is unexpected that systemic injection of the GRP receptor antagonist enhanced scratching elicited by 5-HT. Injection (id) of the GRP receptor antagonist also enhanced 5-HT-evoked scratching (Fig. 4E) , suggesting that local GRP receptors participated in this effect. In addition, id injection of the GRP receptor antagonist itself elicited scratching. One possibility is that peripheral and central GRP receptors play different roles in itch. Speculatively, a peripheral GRP receptor may constitutively inhibit itch signaling, such that blocking the GRP receptor reduces local inhibition to elicit and enhance scratching. Another possibility is that RC-3095 may act as a partial agonist but not full antagonist, such that RC-3095 activates GRP receptors expressed at peripheral sites. This is supported by a recent study showing that id injection of GRP elicited scratching (Andoh et al. 2011) . In either case, speculatively, 5-HT may sensitize this itch signaling pathway. The present results need to be taken into consideration in developing GRP receptor antagonists for the treatment of itch.
Of the pruritogen-responsive DRG cells, 19.1% and 25.1% were immunopositive for SP and GRP, respectively. These proportions of peptidergic sensory neurons may be sufficient to transmit certain types of itch signals. However, pruritogenevoked scratching was reduced only partially by antagonists of the NK-1 or GRP receptor, suggesting that an additional mediator other than SP or GRP is also involved in spinal transmission of itch signaling. NK-B, encoded by the tachykinin-2 gene, is a member of the tachykinin peptides, along with SP, and is a possible candidate as a neuropeptide transmitter in spinal itch transmission. However, a recent study revealed that tachykinin-2 null mice exhibited normal scratch responses to compound 48/80, chloroquinine, SLIGRL-NH2, and methyl-serotonin, implying that NK-B is not involved in the spinal transmission of itch signaling (Mar et al. 2012) . It is widely accepted that glutamate acts as an excitatory spinal neurotransmitter. Most peptidergic and nonpeptidergic DRG neurons express vesicular glutamate transporters, which are responsible for the uptake of the glutamate into synaptic vesicles (Brumovsky et al. 2007; Scherrer et al. 2010 ). GRP receptor-expressing spinal neurons are thought to be essential for transmission of itch signaling (Sun et al. 2009 ). It was recently reported that GRP receptor-expressing spinal neurons are activated by glutamate-rather than GRP-release from primary afferents (Koga et al. 2011; Sun et al. 2009 ). Thus glutamate is a good candidate as an additional spinal neurotransmitter for itch. 
